Global Butorphanol Market Overview:
Butorphanol is used to treat moderate to severe pain. It is also used as part of anesthesia for surgery, or during early labor. Also, Butorphanol is an opiate agonist used by some veterinarians primarily as an anti-tussive, to help alleviate coughing. In some cases, it can be used to treat pain in animals, such as colic in horses, or as a pre-anesthetic.
- Increasing Demand for Long-Term Pain Management among the Geriatric Population
- Growing Prevalence of Animal Diseases Causing Pain and Inflammation
- Growth in Clinical Trials
- Side Effects of the Butorphanol
- Increasing Popularity of Non-Conventional and Non-Pharmaceutical Treatment Techniques
- Untapped Emerging Markets
- Low Animal Healthcare Awareness in Emerging Markets
- Stringent Regulatory Approval Process for Pain Management Drugs
The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to avail of competitive advantage through combined collaborations.
Some of the key players profiled in the report are Hikma Pharmaceuticals plc (United Kingdom), Richter Pharma Ag (Austria), Mylan N.V. (United States), Pfizer Inc. (United States), Sanochemia Pharmazeutika AG (Austria), Novex Pharma (Egypt), Selectavet (Germany), Bristol Myers Squibb (United States), Dechra Pharmaceuticals PLC (United Kingdom) and Merck Group (Germany). Additionally, following companies can also be profiled that are part of our coverage like Apothecon Pharmaceuticals (India) and Faunapharma (Finland). Analyst at AMA Research see United States Players to retain maximum share of Global Butorphanol market by 2026. Considering Market by Drug, the sub-segment i.e. Prescripted will boost the Butorphanol market.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Butorphanol market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Butorphanol market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Butorphanol, Suppliers of Butorphanol, Wholesalers, Distributors, and Retailers of Butorphanol, Healthcare Industry, Governmental Bodies and Research Firms.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.